The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer

Basit Öğe Kaydı
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorDemir, Hacer
dc.contributor.authorAraz, Murat
dc.contributor.authorBaykara, Meltem
dc.contributor.authorAykan, Nuri Faruk
dc.date.accessioned2024-02-23T13:59:45Z
dc.date.available2024-02-23T13:59:45Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractIntroduction Although several clinical factors which show the benefit of adjuvant chemotherapy (AC) in early-stage colon cancer use for evaluating the risk of relapse, there is no consensus on which risk factors are more reliable. In this study, we evaluated both the utility of MSI and the daily practice of the Turkish oncologists in stage II and III colon cancer. Material and Method We conducted an online questionnaire which was consisting of twenty questions including the treatment choices and duration about stage II-III colon cancer depending on sidedness and risk factors for relapse. Results More than 65% of the oncologists declared the use of MSI testing in stage II colon cancer without considering any risk factors. In stage 3 colon cancer oncologists had an equal decision to do or not to do in MSI testing. More than 50% of the oncologists had preferred XELOX protocol in high-risk stage II (T4N0) colon cancer, while three out of four preferred observation in low-risk stage II (T3N0) patients without risk factors. Two-thirds of the oncologists had preferred 6 months of treatment in stage II colon cancer with at least one risk factor. Conclusion Turkish oncologists participating to this trial had declared conflicting results about adjuvant treatment in early-stage colorectal cancer in their daily practice compared with the updated guidelines, especially, MSI evaluation utility in stage III colon cancers, adjuvant chemotherapy (AC) duration, and oxaliplatin adding to AC in elderly and stage II patients.en_US
dc.identifier.doi10.1007/s12029-020-00542-5
dc.identifier.endpage63en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue1en_US
dc.identifier.pmid33159235en_US
dc.identifier.scopus2-s2.0-85095697945en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage57en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00542-5
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11315
dc.identifier.volume53en_US
dc.identifier.wosWOS:000587097600001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColon Canceren_US
dc.subjectAdjuvant Treatmenten_US
dc.subjectMicrosatellite Instabilityen_US
dc.subjectDuration Of Treatmenten_US
dc.subjectMsi Testingen_US
dc.titleThe View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu